#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16934	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2268	727.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1388	1388	C	1136	C	991	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31352	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3874	792.0	0	.	n	.	0	T695C	SNP	695	695	T	1288	1288	C	1216	C,A	1098,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31352	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3874	792.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1930	1930	A	885	A	826	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31352	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3874	792.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2564	2564	C	1008	C	902	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31352	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3874	792.0	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2638	2638	G	1040	G,C	927,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31352	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3874	792.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3190	3190	C	1020	C	884	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1118	folP	852	852	100.0	folP.l15.c4.ctg.1	1666	64.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1047	1049	AGC	104;104;105	A;G;C	100;101;102	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2848	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3522	78.2	1	SNP	p	S91F	0	.	.	271	273	TCC	709	711	TCC	123;123;121	T;C;C	110;113;110	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2848	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3522	78.2	1	SNP	p	D95N	0	.	.	283	285	GAC	721	723	GAC	122;123;122	G;A;C	114;114;112	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	2848	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3522	78.2	1	SNP	p	D95G	0	.	.	283	285	GAC	721	723	GAC	122;123;122	G;A;C	114;114;112	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	824	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1262	62.4	1	SNP	p	G45D	1	.	.	133	135	GAC	403	405	GAC	100;101;100	G;A;C	92;90;92	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	618	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1071	55.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2686	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3135	82.8	1	SNP	p	D86N	0	.	.	256	258	GAC	578	580	GAC	108;108;112	G;A;C	107;104;110	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2686	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3135	82.8	1	SNP	p	S87I	0	.	.	259	261	AGT	581	583	AGT	113;112;111	A;G,T;T	112;109,1;110	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2686	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3135	82.8	1	SNP	p	S87R	0	.	.	259	261	AGT	581	583	AGT	113;112;111	A;G,T;T	112;109,1;110	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2686	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3135	82.8	1	SNP	p	S87W	0	.	.	259	261	AGT	581	583	AGT	113;112;111	A;G,T;T	112;109,1;110	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	2686	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3135	82.8	1	SNP	p	S88P	0	.	.	262	264	TCC	584	586	TCC	111;112;109	T;C;C	109;110;108	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2320	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2669	83.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1595	1597	GGC	79;79;78	G;G;C	74;74;73	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1284	1286	GCA	189;190;190	G;C;A	164;166;166	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1287	1289	ATC	186;186;187	A,T;T;C	166,1;168;167	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1299	1301	GTG	193;192;190	G;T;G	172;170;169	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1299	1301	GTG	193;192;190	G;T;G	172;170;169	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1803	1805	ACC	110;110;109	A;C;C	93;96;94	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1857	1859	GCG	71;72;72	G;C;G	68;68;68	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1857	1859	GCG	71;72;72	G;C;G	68;68;68	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1980	1982	GGC	79;78;78	G;G;C	69;67;68	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1989	1991	GGC	61;61;60	G;G;C	54;53;52	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2844	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2423	113.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2007	2009	CCG	42;41;41	C;C;G	40;38;39	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4984	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2974	161.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1230	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1501	77.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	311	311	C	68	C	62	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	R307E	NONSYN	919	921	AGA	189	191	GAA	3;3;2	G;A;A	3;3;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	201	203	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	E312D	NONSYN	934	936	GAA	204	206	GAC	1;1;1	G;A;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	210	212	ATC	1;1;1	A;T;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	216	218	TCG	1;1;1	T;C;G	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	222	224	GCC	1;1;2	G;C;C	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	225	227	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	228	230	GCC	2;2;3	G;C;C	1;2;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	154	porB1a	984	156	92.31	porB1a.l6.c30.ctg.3	329	6.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	234	236	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	A26V	NONSYN	76	78	GCC	353	355	GTC	124;123;123	G;T;C	114;113;113	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	E48G	NONSYN	142	144	GAA	419	421	GGA	154;153;158	G;G;A	138;137;137	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	T87A	NONSYN	259	261	ACT	536	538	GCT	129;127;126	G;C;T	117;115;114	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	542	544	AGC	124;124;123	A;G;C	112;113;111	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	.	MULTIPLE	358	359	AA	634	635	CG	115;112	C;G	106;104	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	.	MULTIPLE	361	362	GA	637	639	CAG	112;112;111	C;A;G	104;101;103	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	N122K	NONSYN	364	366	AAC	641	643	AAA	115;120;123	A;A;A	106;109;112	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	A125T	NONSYN	373	375	GCT	650	652	ACT	137;137;126	A;C;T	122;127;116	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	N134S	NONSYN	400	402	AAT	677	679	AGT	131;132;139	A;G;T	123;125;129	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	E137K	NONSYN	409	411	GAA	686	688	AAA	130;130;129	A;A;A	125;125;124	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	K143E	NONSYN	427	429	AAA	704	706	GAA	127;131;132	G;A;A	122;126;127	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	728	730	GCA	142;142;143	G;C;A	134;133;134	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	836	838	CAA	221;221;218	C;A;A	190;190;187	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	N189S	NONSYN	565	567	AAC	842	844	AGC	206;208;208	A;G;C	173;172;173	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	M209I	NONSYN	625	627	ATG	902	904	ATC	175;175;179	A;T;C	157;155;161	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	0	.	p	.	0	E210fs	FSHIFT	628	628	G	905	905	G	178	G	160	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	1	SNP	p	G120K	1	.	.	358	360	AAG	634	636	CGG	115;112;112	C;G;G	106;104;104	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	1	SNP	p	A121D	1	.	.	361	363	GAC	637	640	CGC	112;111;115	C;G;C	104;103;106	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	1832	porB1b	1041	1041	96.56	porB1b.l15.c4.ctg.1	1469	120.5	1	SNP	p	D121N	0	.	.	361	363	GAC	637	640	CGC	112;111;115	C;G;C	104;103;106	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7110	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4661	148.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1861	1863	AAT	147;149;151	A;A;T	130;132;133	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	698	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1131	60.2	1	SNP	p	V57M	1	.	.	169	171	ATG	550	552	ATG	135;132;136	A;T;G	119;117;121	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
